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Abstract
Purpose: Although chronic hepatitis C virus (HCV) infection has been treated with the combination of interferon
alpha (IFN-α) and ribavirin (RBV) for over a decade, the mechanism of antiviral synergy is not well understood. We
aimed to determine the synergistic antiviral mechanisms of IFN-α and RBV combination treatment using HCV cell
culture.
Methods: The antiviral efficacy of IFN-α, RBV alone and in combination was quantitatively measured using HCV
infected and replicon cell culture. Direct antiviral activity of these two drugs at the level of HCV internal ribosome
entry site (IRES) mediated translation in Huh-7 cell culture was investigated. The synergistic antiviral effect of IFN-α
and RBV combination treatment was verified using both the CalcuSyn Software and MacSynergy Software.
Results: RBV combination with IFN-α efficiently inhibits HCV replication cell culture. Our results demonstrate that
IFN-α, interferon lambda (IFN-λ) and RBV each inhibit the expression of HCV IRES-GFP and that they have a
minimal effect on the expression of GFP in which the translation is not IRES dependent. The combination treatments
of RBV along with IFN-α or IFN-λ were highly synergistic with combination indexes <1. We show that IFN-α treatment
induce levels of PKR and eIF2α phosphorylation that prevented ribosome loading of the HCV IRES-GFP mRNA.
Silencing of PKR expression in Huh-7 cells prevented the inhibitory effect of IFN-α on HCV IRES-GFP expression.
RBV also blocked polyribosome loading of HCV-IRES mRNA through the inhibition of cellular IMPDH activity, and
induced PKR and eIF2α phosphorylation. Knockdown of PKR or IMPDH prevented RBV induced HCV IRES-GFP
translation.
Conclusions: We demonstrated both IFN-α and RBV inhibit HCV IRES through prevention of polyribosome
formation. The combination of IFN-α and RBV treatment synergistically inhibits HCV IRES translation via using two
different mechanisms involving PKR activation and depletion of intracellular guanosine pool through inhibition of
IMPDH.
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Introduction
HCV infection leads to a fast progression to chronic liver
disease, liver cirrhosis and hepatocellular carcinoma [1]. There
are 160 million people infected with HCV representing a major
public health problem worldwide [2]. HCV is an enveloped
positive-stranded RNA virus that belongs to the Flaviviridae
family. This family includes yellow fever and dengue viruses,
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which also affect humans [3]. The genome of HCV is organized
into a highly conserved 5’-untranslated region (5’ UTR), a large
open reading frame (ORF) and a 3’-untranslated region (3’
UTR). The 5’ UTR of HCV genome binds to the host ribosome
using the internal ribosome entry site (IRES) mechanism that
facilitates translation of HCV protein [3,4]. The HCV genome
contains a large open reading frame (ORF) that encodes for a
polyprotein 3011 amino acid long. The polyprotein is
proteolytically processed in the endoplasmic reticulum (ER)
membrane into 10 different mature viral proteins by the cellular
and viral protease [3]. The core protein and the two
glycoproteins E1 and E2 are structural proteins; they are
required for the formation of the viral particle, as well as
assembly, export and infection. The non-structural (NS)
proteins include the p7 ion channel, the NS2 protease, the NS3
serine protease and RNA helicase, the NS4A polypeptide (a
cofactor for NS3 protease), the NS4B, the NS5A protein, and
the NS5B RNA-dependent RNA polymerase, which are
required for replication of the viral genome. The NS proteins
(protease and polymerase) have been the targets of intense
research efforts for the development of antiviral drugs against
HCV. The highly conserved 3’ UTR present at the very end of
the HCV genome is important for the initiation of viral RNA
replication [5]. HCV infection is initiated by the attachment and
entry of virus particles into the host cells by receptor mediated
endocytosis [6].
IFN-α and RBV, along with one of the protease inhibitors, is
the standard-of-care for chronic HCV 1a infection [7]. Recently
the FDA approved two protease inhibitors (Telaprevir and
Boceprevir) that are specific to HCV genotype 1 virus NS3
sequences. IFN-α in combination with RBV is still used as the
standard treatment for other HCV genotypes. Ribavirin is a
guanosine analogue used for the treatment of a number of
RNA viruses including the respiratory syncytial virus (RSV),
Lass fever virus and HCV [8]. IFN-α and RBV combination
therapy is more effective in the treatment of chronic HCV
infection than treatment with a single agent [9]. Ribavirin is a
synthtic guanosine nucleoside analogue (1-b-D-
ribofuranosyl-1,2,4-triazole-3-carboxamide) which has been
shown to be metabolized intracellularly into ribavirin mono
(RMP), di- (RDP) and triphosphate (RTP) [10]. Although RBV is
extensively used to treat patients with HCV-infection the direct
antiviral mechanism by which the compound inhibits viral
replication remains largely elusive [8]. Furthermore, the
mechanism by which the combination of RBV and IFN-α
combination improves the treatment response is unclear [11].
Understanding the synergistic antiviral mechanisms of IFN-α
and RBV action using the improved HCV cell culture system is
important and may open new therapeutic interventions to
improve the clinical response.
In our present study, we addressed the mechanism of IFN-α
and RBV combination synergy by using full-length infectious
cell culture, replicon model and a sub-genomic HCV IRES
expression model. We observed that IFN-α and RBV each
directly inhibited translation of HCV IRES by blocking
polyribosome formation. Our results suggest that IFN-α and
RBV each activate PKR and eIF-2α phosphorylation which
blocks HCV IRES mediated translation and synergistically
inhibits HCV replication. Furthermore, RBV mediated inhibition
of IMPDH activity also contributes to the blockadge of
polyribosome loading.
Materials and Methods
Cell culture and reagents
Human hepatoma cell lines, Huh-7 and Huh-7.5 were
maintained in Dulbecco’s modified eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), non-
essential amino acids and sodium pyruvate. The stable S3-
GFP replicon cell line (HCV JFH1 2a) was maintained in
DMEM and 10% FBS supplemented with G-418 (1 µg/mL) as
described in our previous study [12]. Full-length Renilla
luciferase (Rluc) reporter based JFH-∆V3-Rluc clone used in
our infectivity assay was a kind gift from Curt H. Hagedorn
Laboratory [13]. A replication defective adenovirus that
expresses T7 RNA polymerase (AdexCAT7) was a kind gift
from Tatsuo Miyamura, National Institute of Infectious Disease,
Tokyo, Japan [14]. Cell culture derived infectious HCV stocks
were prepared from the supernatants of Huh-7.5 cells as
described previously [15]. Recombinant IFN-α 2b (Intron-A)
was purchased from Schering-Plough (New Jersey, USA).
Ribavirin, Cycloheximide and Guanosine were purchased from
Sigma Chemical Company (St. Louis, MO, USA). Interferon
lambda 1 (IL-29) was obtained from Peprotech, Rocky Hills,
NJ, USA.
IFN-α and RBV combination treatment in sub-genomic
replicon cell line and in infected HCV cell culture
S3-GFP replicon cells were cultured in presence of different
concentrations of IFN-α and RBV alone and in combination for
72 hours. The antiviral effect of IFN-α and RBV combination
treatment was evaluated by GFP expression under a
fluorescence microscope and quantified by flow cytometric
analysis. Huh-7.5 cells were infected with JFH-∆V3-Rluc virus
(MOI 0.1) using a standard protocol [15]. After 48 hours,
infected cultures were treated with increasing concentrations of
IFN-α or RBV alone or in combination. After 72 hours, the
antiviral effect of IFN-α and RBV treatment was measured by
NS5A-Rluc activity. Total protein concentration was measured
by the Bradford method and luciferase activity was expressed
in per micro-gram of total protein. HCV core protein expression
was also measured by immunocytochemistry using the
following protocol. Infected Huh-7.5 cells with or without IFN-α
treatment were mounted onto a glass slide via the cytospin
method. The cells were washed in PBS, fixed in chilled acetone
for 15 minutes and then permeabilized by Reveal Decloaker
RTU (Biocare Medical, RV 100) reagent for 25 minutes. Slides
were cooled for 25 minutes and blocking was performed with
Background Sniper (Biocare Medical, BS966) for 10 minutes at
room temperature. The cells were incubated with monoclonal
anti-core antibody (Thermo Scientific, Pierce HCV-core antigen
specific mouse monoclonal antibody, Ma1-080) at 1:200 diluted
with Da Vinci Green Diluent (Biocare Medical, PD900) for 1 h
at room temperature. Cells were washed three times in Tris-
buffered saline (TBS) pH 8.0, and incubated with MACH 4
mouse probe (Biocare Medical, UP534) for 10 minutes and
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then incubated with MACH4 HRP Polymer (Biocare Medical,
MRH534) for 30 minutes. Next, the cells were treated with
diaminobenzidine (DAB) chromogen (Dako Cytomation,
Carpinteria, CA) for 5 minutes. The slides were counterstained
with hematoxylin for 30s and Tacha’s bluing Solution (Biocare
Medical, HTBLU) for 30 s, dehydrated, mounted and observed
by light microscopy.
IFN-α and RBV effect on HCV-IRES mediated
translation
A chimeric sub-genomic clone of HCV IRES and GFP (pHCV
IRES-GFP) was used to determine the antiviral mechanisms of
IFN-α and RBV as described previously [16]. Plasmids pEGFP-
N1 and pDsRed-N1 expressing GFP and RFP (red
fluorescence protein) respectively from a human
cytomegalovirus (CMV) promoter by a non-IRES dependent
mechanism were used as a control (BD Biosciences,
Clonetech, Palo Alto, CA). Huh-7 cells (1X104 cells/well) were
infected with AdexCAT7 (10 pfu/cell) for 2 hours at 370C, and
then transfected with pHCVIRES-GFP clone using the X-
tremeGENE 9 transfection reagent (Roche Diagnostics,
Indianapolis, IN). The pEGFP-N1 and pDsRed-N1 plasmid was
transfected without addition of AdexCAT7 to the cells. Huh-7
cells were first transfected with 1µg of HCV IRES-GFP or
pEGFPN1 or pDsRedN1 plasmid and treated with IFN-α
(10-1000 IU/mL) and RBV (10-40 µg/mL). After 24 hrs, GFP
expression was monitored under a fluorescence microscope
(Olympus IX 70, Germany) and quantified by flow cytometric
analysis. Transfected cells were examined with a fluorescent
microscope at 484 nm for the expression of GFP and at 340
nm for Hoechst 33342 stain. Nuclear stain was superimposed
over cytoplasmic GFP using Adobe Photoshop computer
software generated the images.
Evaluation of synergy interaction at the level of HCV-
IRES mediated translation
A Sub-genomic construct (pHCV-IRES-RLuc) with T7
promoter, HCV IRES-Rluc fusion, 3’ UTR of HCV, a cDNA
copy of the autolytic ribozyme from antigenomic strand of the
hepatitis delta virus and T7 transcriptional terminator
sequences was used to study HCV-IRES mediated translation.
Huh-7 cells were transfected with pHCV-IRES-RLuc plasmid
using the same procedure described above. The cells were
treated with IFN-α (10-1000 IU/mL) and RBV (10-80 µg/mL)
alone and combination immediately after transfection and
incubated at 37oC for 24 hours. After 24 hours, the cells were
washed with PBS, lysed and Renilla luciferase activity was
measured (Luman LB9507, EG & G, Berthold, Berlin,
Germany). The consistency of the results was maintained by
quantifying emissions from triplicate wells for each treatment.
IFN-λ also shows good antiviral effect against HCV
(unpublished data). To determine the combinatory effect of
IFN-α, IFN-λ and RBV, Huh-7 cells transfected with pHCV-
IRES-RLuc plasmid were treated with 0, 10, 100, 1000 IU/mL
of IFN-α 0 10 20 50 100 μg/mL IFN-λ and 0, 10, 20, 40 µg/mL
of RBV. Renilla luciferase values were analyzed by using the
CalcuSyn software (Biosoft). This program uses the median-
effect principle to delineate the interaction between these two
drugs. For each combination, the program generates a
combination index (CI) based on the equation below described
by Chou et al [17,18]. A combination index (CI) of <1 means
synergism, CI=1 means additive and CI>1 means antagonism.
Drug–drug combination analysis of IFN-α and RBV was
performed with the MacSynergy II program [19,20].
Polyribosome fractionation and Northern blot analysis
To examine whether IFN-α and RBV treatment inhibits
translation by preventing the loading of polyribosomes on the
IRES-GFP mRNA, polysome analysis was performed using
sucrose density gradient centrifugation. Huh-7 cells were
transfected with pHCV IRES-GFP clone using a two-step
transfection procedure. After transfection, cells were treated
with IFN-α (1000 IU/mL) or RBV (40 µg/mL) and after 24 hours,
the expression of GFP was examined. The polysome analysis
was performed using a protocol described earlier [21]. Briefly,
transfected Huh-7 cells were washed twice with ice-cold PBS
pH-7.2 containing 100µg/mL cycloheximide. The cells were
lysed by 200 µl of polysomes lysis buffer containing 100 mM
KCl, 5mM MgCl2, 10 mM HEPES, pH7.4, 100 µg/mL
cycloheximide, 0.5% Nonidet P-40, and 1000 units/mL RNase
inhibitor (Ambion Inc, Austin, TX). The cell lysate was passed
four times through a 27-gauge needle to ensure complete cell
lysis. Nuclei were pelleted by centrifugation at 12,000 rpm for 5
minutes. The supernatant was collected and centrifuged an
additional time to ensure the removal of any nuclei. The
resulting supernatant was layered on a linear 15-60% (w/v)
sucrose gradient in polysome gradient buffer (100 mM KCl, 5
mM Mg Cl2 and 10 mM HEPES pH 7.4) and centrifuged at
36,000 rpm for 2 hours at 4°C in a Beckman SW41 rotor. The
distribution of ribosomal RNA along the sucrose density
gradient fractions was determined using a polysome
fractionator (Teledyne ISCO, Brandel, Inc, Gaithersburg,
Maryland). Total RNA was isolated from the sucrose density
fractions by treating with proteinase K solution (0.2 M Tris-HCl,
pH 7.5, 25 mM EDTA, 0.3 M NaCl, 2% SDS, and 250 µg/mL
proteinase K, RNase free DNase-I 10 U/mL). Half of the RNA
samples were subjected to Northern blot analysis to examine
the distribution of HCV IRES-GFP mRNA in each fraction.
Identical experiments were performed to determine the effect of
RBV on the distribution of HCV IRES-GFP mRNA in the
polysome fractions. Control experiments were performed using
the pEGFP-N1 plasmid to determine the effect of IFN-α on the
distribution of mRNA in the polysome fraction whose translation
occurs via cap-dependent mechanism. To detect the HCV-
IRES mRNA in the polysome fractions an anti-sense 32P
labeled riboprobe (106 cpm/mL) targeted to the highly
conserved 5’ UTR of HCV genome was used. To detect EGFP
mRNA in the polysome fractions, an anti-sense 32P labeled
RNA probe (106 cpm/mL) targeted to the GFP was used.
Northern hybridization was performed using the ULTRAhyb
reagent (Ambion Inc, Austin, TX) at 680C for 16 hours. Blots
were then washed twice for 15 min each at 370C using a
washing solution (0.1X SSC-0.1% SDS), followed by two 15
min washes at 370C using a washing solution (0.1X SSC-0.1%
SDS). The membrane was exposed for autoradiography using
Bio Max X-ray film (Kodak imaging system). Proteins bound to
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polyribosomes were isolated using a standard protocol [22].
Briefly, sucrose gradient fractions were precipitated by an
addition of cold trichloroacetic acid to a final volume of 10%
and were incubated on ice for 30 minutes. This step was
followed by centrifugation at 20,000g for 15 min at 4°C. Pellets
were washed once with 5% TCA and once with cold acetone.
Finally, protein pellets were resuspended in a sample buffer
(50 mM Tris at pH 6.8, 2% SDS, 2% glycerol) and 1% β-
mercaptoethanol or 1 mM DTT, heated at 65°C, and processed
for SDS-PAGE. Protein in the or transferred to nitrocellulose for
Western blot.
Western blot analysis
Protein lysates from cells were prepared after treatment with
IFN-α and RBV for 24 hours. Equal amounts of protein were
resolved on SDS-PAGE gels. The antibodies to PKR, eIF2α,
peIF2α (Ser51), β-actin, PKR, anti-mouse IgG, and anti-rabbit
IgG HRP-linked antibody were purchased from Cell Signaling,
Beverly, MA. Antibody to p-PKR (pT446) was obtained from
Epitomics, Burlingame, CA. Antibody to IMPDH was obtained
from Santa Cruz, Dallas, USA. Twenty microgram of proteins
were resuspended in sample buffer (50 mM Tris at pH 6.8, 2%
SDS, 2% glycerol) and 1% β-mercaptoethanol or 1 mM DTT,
heated at 65°C, and processed for SDS-PAGE. Proteins were
transferred to nitrocellulose membrane and Western blotting
was performed using a standard protocol.
Knockdown of PKR and IMPDH mRNA
siRNA duplexes targeting the coding regions of human
IMPDH1 (Qiagen, catalog no. SI02781044), PKR (Qiagen,
SI02223018) and unrelated control siRNA were obtained from
Qiagen. Huh7 cells were transfected with the indicated siRNA
duplexes using Oligiofectamine (Invitrogen, CA). After 6 hours
of siRNA treatment the cells were transfected with the IRES-
GFP sub-genomic construct and then treated with either IFN-α
or RBV to examine translational inhibition.
Results
IFN-α and RBV synergistically inhibit HCV replication in
replicon and full-length infectious cell culture models
The genomic and sub-genomic clones for HCV genotype 2a
used to develop the HCV replication model are shown (Figure
S1A). We first measured the cytotoxic effects of IFN-α and
RBV treatment alone and in various combinations using Huh-7
cells and S3-GFP replicon cell line by a MTT assay. Ribavirin
up to 200 µg/mL did not show any cytotoxicity (Figure S2A).
The viability of S3-GFP cells were more than 90% at 48 hours
when treated with RBV (10-60 µg/mL) and IFN-α (10-1000
IU/mL) alone (Figure S2B) or in combination (Figure S2C).
Based on the MTT assay results, concentration of RBV
(10-40µg/ml) permitting high viability was used for subsequent
antiviral assays. The antiviral effect of IFN-α and RBV
combination treatment in S3-GFP replicon cells after 72 hours
was confirmed by the measurement of GFP expression under a
fluorescence microscope (Figure 1A) and the expressed GFP
was quantified by flow cytometric analysis (Figure 1B). The
sub-genomic replicon system does not produce infectious virus
due to lack of the structural proteins. Antiviral effect of IFN-α
and RBV combination treatment was measured using an
infectious cell culture model using the JFH1-Rluc chimera
virus. The IFN-α and RBV treatment gradually reduced the
RLuc activity in a dose dependent manner (Figure 1C). The
inhibition of HCV replication was significant at RBV 20µg/mL
with IFN-α (100 IU/mL) and RBV 40µg/mL with IFN-α (250 IU/
mL). We verified the antiviral effect of combination treatment by
measuring HCV core protein expression by immunostaining
(Figure 1D). The number of HCV core positive cells in five
different high power fields (hpf) were counted and compared
with untreated control (Figure 1E).
IFN-α, IFN-λ1 and RBV combination treatment
synergistically inhibit HCV IRES mediated translation
Previously we reported that type I and Type II IFN inhibit
HCV replication by targeting the 5’ UTR of HCV RNA genome
used for IRES mediated translation [23]. Here we examined
whether IFN-α and RBV combination treatment could also
inhibit the HCV IRES mediated translation. The mechanisms of
IFN-α and RBV action on HCV translation were examined
using HCV IRES-GFP or HCV IRES-RLuc based subgenomic
clones (Figure S1B). Plasmid clones pEGFP-N1 and pDsRed-
N1 were used as controls to examine the effect of IFN-α and
RBV treatment on the expression of GFP or RFP by non-IRES
mechanisms (Figure S1B). High-level expression of GFP from
HCV IRES in Huh-7 cells was achieved by using two-step
transfection procedures that first involve infection with
replication defective adenovirus that expresses T7 RNA
polymerase (AdexCaT7), followed by transfection with a
transcription plasmid (Figure S1C). The HCV IRES mediated
translation of GFP was inhbited by both IFN-α and RBV at
increasing concentration of both the drugs as evidenced by
fluorescence imaging (Figure 2A) and Western blot analysis
(Figure 2B). The cap dependent translation of GFP or RFP was
not inhibited by addition of these two drugs (Figures S3A and
S3B). IFN-α and RBV show maximum HCV IRES inhibition at
1000 IU/mL and 40 µg/mL respectively. Results of Northern
blot analysis indicate that the intracellular IRES GFP mRNA is
relatively stable in the IFN-α and RBV treatment. There is no
significant difference in the stability of HCV IRES-GFP mRNA
in Huh-7 cells treated with increasing concentrations of IFN-α
(10 to 1000 IU/mL) compared to GAPDH mRNA level used as
a control (data not shown). These results indicate that IFN-α
and RBV treatment inhibit translation of HCV IRES-GFP
without altering the stability of intracellular HCV IRES sub-
genomic mRNA. Interferon lambda (IFN-λ1) is a type III IFN,
which has been found to have a sustained antiviral activity
against HCV (unpublished results). We quantified the relative
antiviral activity of IFN-α, IFN-λ1 and RBV at the level of HCV
IRES translation using a HCV IRES Rluc plasmid (Figure S1B).
Huh-7 cells were transfected with HCVIRES-Rluc plasmid and
then treated with different concentrations of IFN-α, IFN-λ1 and
RBV alone and in combination. The antiviral activity of
combination treatment was measured by Renilla luciferase
activity per microgram of cellular protein. The results presented
in Figure 3A show that IFN-α, IFN-λ1 and RBV each inhibits
Synergy Mechanism of IFN-α and RBV
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72791
HCV replication in a dose-dependent manner. The combination
of IFN-α and IFN-λ1 at the level of HCV-IRESRLuc expression
was examined (Figure 3B). Combination treatment of IFN-α
with RBV (Figure 3C) and IFN-λ1 with RBV (Figure 3D)
showed a stronger inhibitory effect on HCV IRES-Rluc
expression. Determination of a synergistic, additive or
antagonstic effect of IFN-α and RBV combination was
performed according to the median effect principle using the
CalcuSyn computer program. The combination treatment of
IFN-α and RBV was highly synergistic with CI values of <1.
Results using CalcuSyn software revealed synergistic
interactions across the entire range of RBV with either IFN-α or
IFN-λ1 combinations tested (Figure 4A and 4B). IFN-α and
IFN-λ1 combination treatment did not show synergistic
inhibition of the HCV IRES-translation (Figure 4C). Analysis of
IFN-α, IFN-λ1 and RBV treatment was subsequently performed
with the MacSynergy II program. The MacSynergy II program
calculated the theoretical additive interactions of the drugs
based on the Bliss Independence mathematical definition of
expected effects for drug–drug interactions. The additive
interactions were calculated from the dose–response. If the
interactions are additive, the resulting surface appeared as
horizontal plane at 0% above the calculated additive surface in
the resulting difference plot. Peaks above this plane is an
indicative of synergy, while depression below the horizontal
plane is an indication of antagonism. This analysis revealed
that RBV treatment in combination with either IFN-α or IFN-λ1
had resulted in strong synergistic interactions (Figure 4G and
4H). In contrast, IFN-α and IFN-λ1 combination treatment show
slightly antagonistic interactions (Figure 4C and 4I). Average
cell inhibition was shown in Figure 4D, 4E and 4F. In
conclusion, synergistic interactions between RBV and IFN
treatments were observed at physiologically relevant
concentrations.
IFN-α and RBV treatment prevents loading of
polyribosome to HCV IRES containing mRNA
The translation of HCV genomic RNA is initiated by the
binding of the host cell ribosome to a highly conserved RNA
sequence called the internal ribosome entry site (IRES),
located in the 5’ UTR. We examined whether inhibition of GFP
expression in the HCV IRES subgenomic clone could have
occurred due to a differential loading of polyribosome. The
upper panel (Figure 5A) shows the separation of 40S, 60S and
80S and polyribosme in the sucrose density gradient using a
Figure 1.  Antiviral effect of IFN-α and RBV combination treatment using a sub-genomic replicon cell line (S3-GFP) and
HCV infected Huh-7.5 cells.  (A) S3-GFP cells were treated with IFN-α and RBV for 72 hours. GFP expression was examined
under a fluorescence microscope. (B) GFP positive cells were quantified by flow cytometric analysis. (C) Infected Huh-7.5 cells
were treated with IFN-α alone, RBV alone and combination for 72 hours. Renilla Luciferase activity of infected cells was measured
and normalized with 1µg of cellular protein. (D) Expression of HCV core protein was measured by immunostaining and (E) core
positive cells in five different high power fields (hpf) at 40X magnification were counted under a light microscope. Quantitative
assessment of the number of HCV positive cells with mean and standard deviation of the combination treatment are compared.
doi: 10.1371/journal.pone.0072791.g001
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polysome fractionator (Teledyne ISCO, BRANDEL). Total RNA
from each gradient fraction was isolated and analyzed by
agarose gel electrophoresis. The location of monosomes and
polysomes was determined by ethidium bromide staining
(Figure 5B). Polysome fractionation of IRES-GFP transfected
Huh-7 cells after treatment with IFN-α or RBV was performed
to examine distribution of HCV IRES-GFP mRNA in the
monosome and polysome fractions. The amount of HCV IRES
containing GFP mRNA associated with each ribosome fraction
was determined by Northern blot analysis using an antisense
RNA probe targeted to the 5’ UTR. Northern analysis of
transfected cells revealed that under a normal translation
condition without treatment, the distribution of HCV IRES-GFP
mRNA gradually increased from monosome to polysome,
suggesting an increased efficiency of ribosome loading and
continued translation. In contrast, IFN-α treatment (IFN+)
resulted in an arrest of the majority of HCV IRES-GFP mRNA
in the monosome peaks and reduction in the polysome
fractions (Figure 5C, lanes 12-14). Similar results were
consistently achieved in three separate experiments. A Similar
mechanism is also operative in the case of RBV treatment.
Polysome analysis was performed using HCV IRES-GFP
transfected cells treated with RBV. The distribution of IRES-
GFP mRNA in the RBV treated (RBV+) cells was found in
monosome peaks and reduction in polysome peaks (Figure 5D,
lanes 10-14). To address the specificity of IFN-α action on the
IRES-GFP mRNA translation, we examined mRNA distribution
using EGFP mRNA after IFN-α or RBV treatment. The
distribution of GFP mRNA in the polysome fractions was
measured by Northern blot analysis using a GFP specific
antisense riboprobe. We found no significant difference in the
distribution of EGFP mRNA between the monosome and
polysome fractions between cells with or without IFN-α (Figure
5E). To correlate the results of HCV IRES-GFP mRNA
distribution profiles in the polysome fractions in the transfected
cells with and without IFN treatment, we performed
comparative analysis by measuring the density of bands seen
in the Northern blot analysis. The band intensity of Northern
blots was measured using TatalLab (TL120) software and the
values were expressed as a percentage of total RNA recovered
in the gradient (Figure 5F). This analysis clearly shows that
both IFN-α and RBV the inhibited loading of polyribosomes to
the HCV-IRES containing mRNA. This type of alternation in the
mRNA distribution was not observed using control mRNA that
is translated via non-IRES mechanism (Figure 5G).
RBV treatment altered the association of IMPDH and
protein kinase R (PKR) with polysome fractions
To determine whether IMPDH levels could be associated
differently in the polysome fractions after RBV treatment which
is why inhibited the HCV IRES mediated GFP translation,
protein extracts were prepared from monosome and polysome
fractions and Western blot analysis was performed. Untreated
cells IMPDH, PKR, and pPKR were detectable throughout the
gradient (Figure 6A). IFN-α treatment induced PKR activation
and eIF2α phosphorylation. The phosphorylated eIF2α protein
was accumulated in the monosome and disome fractions but
Figure 2.  IFN-α and RBV each inhibited the internal ribosome entry site (IRES) mediated translation of green fluorescence
protein (GFP).  Huh-7 cells were infected with T7-expressing adenovirus. After 2 hrs, HCV IRES-GFP plasmid was transfected and
then treated with indicated concentration of IFN-α and RBV. (A) HCV IRES mediated GFP expression was monitored under
fluorescent microscopy. (B) Inhibition of GFP expression was further confirmed by Western blot analysis in both IRES and non-
IRES mechanisms. β-actin is used as loading controls.
doi: 10.1371/journal.pone.0072791.g002
Synergy Mechanism of IFN-α and RBV
PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e72791
absent in the polysome fractions (Figure 6B, lane 6-10).
Ribavirin treatment accumulated the IMPDH levels in the
monosome and disome fractions but not in the polysome
fractions (Figure 6C). Activated pPKR and peIF2α were also
detected in the monosome and disome fractions but not in the
polysome fractions (Figure 6C, lanes 7-10). These results
indicated that RBV treatment inhibited distribution of cellular
IMPDH, which accumulated in the lower density ribosome
fractions.
PKR and IMPDH are required for IFN-α and RBV
mediated inhibition of HCV IRES-GFP translation
We found the phosphorylation of PKR and eIF2α was
increased due to IFN-α or RBV treatment (Figure 7A). Ribavirin
is a synthetic nucleoside analog and known inhibitor of IMPDH
enzyme. Ribavirin or IFN-α treatment did not increase or
decrease the expression of IMPDH level (Figure 7A). Inhibition
of IMPDH and PKR levels by siRNA restored the inhibitory
action of RBV on HCV IRES-GFP translation (Figure 7B and
C). Inhibition of IMPDH activity by RBV is known to decrease
the intracellular level of guanosine nucleotide pools resulting in
the antiviral activity. Pretreatment with increased concentration
of guanoside indeed neutralized the RBV mediated IRES-GFP
translation (Figure 7D). Depletion of the GTP pool caused by
the inhibition of IMPDH enzyme activity due to RBV contributes
to the inhibition of HCV IRES-GFP translation. We also verified
that the inhibition of PKR by siRNA prevented IFN-α mediated
inhibition of HCV IRES-GFP translation (Figure 7E and F).
These results suggest that PKR and IMPDH are involved in the
IFN-α and RBV mediated synergistic inhibition of HCV IRES
mediated translation.
Discussion
Molecular studies for determining IFN-α antiviral
mechansims against HCV are possible due to the availability of
highly efficient HCV cell culture systems. Many investigators,
including our laboratory, have shown that IFN-α effectively
inhibits HCV replication in cell culture model [23,24]. IFN-α
binds to the cell surface receptors leading to the activation of
Janus kinase signal transducer and activator of transcription
(Jak-Stat) pathway. Activation of cellular Jak-Stat pathway
results in the phosphorylation and nuclear translocation of the
Stat-IRF9 complex to initiate antiviral gene transcription [25]. A
number of key antiviral proteins are induced through the
activation of the Jak-Stat pathway including the double
stranded RNA-activated protein kinase (PKR), 2’5’-
oligoadenylate synthethase (2’5’ OAS) and MxA. Studies have
shown that IFN-α induced antiviral activity is mediated by
interferon inducible ISGs [26]. Mechanisms of IFN-α antiviral
Figure 3.  Different combinations of IFN-α, RBV, and IFN-λ inhibits HCV IRES Rluc mediated translation.  Huh-7 cells were
infected with T7-expressing adenovirus. After 2 hrs, HCV IRES-RLuc plasmid was transfected and then treated with indicated
concentration of IFN-α, IFN-λ and RBV. The concentration dependent inhibition of Renilla luciferase activity by (A) IFN-α, RBV, and
IFN-λ single treatment;(B) Combination of IFN-α + IFN-λ; (C) Combination of IFN-α + RBV and (D) Combination of IFN-λ + RBV.
doi: 10.1371/journal.pone.0072791.g003
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activity through the inhibition of HCV IRES mediated translation
are supported by a number of studies [27–31]. The newly
discovered type III IFN called IFN-λ also inhibits IRES
mediated translation of HCV and hepatitis A [32]. There is an
agreement that Type I, Type II and Type III IFN inhibit HCV
replication by blocking at the level of HCV IRES mediated
translation that involves the PKR induced phosphorylation of
eIF2α [27,28]. The eIF2α is an eukaryotic initiation factor
required for protein translation [33]. This eIF2 protein exists as
heterotrimer consisting of eIF-α, eIF-beta and eIF-gamma. The
eIF2 protein complexes with GTP and the initiator t-RNA to
form the 43S pre-initiation complex. The 43S pre-initiation
complex binds to AUG codon on the target mRNA to initiate
protein translation. The dissociation of the complex occurs
when the eIF2 to hydrolyzes its GTP by eIF5 (a GTPase-
activating protein). This conversion causes the eIF-2-GDP to
be released from the 48S complex and translation to begin
after recruitment of 60S ribosome used and formation of 80S
initiation complex. With the help of guanine nucleotide
exchange factor eIF2-beta, the eIF2-GDP is exchanged to
eIF2-GTP, which initiates another round of translation. The
phosphorylation of eIF2α inhibits recycling of this initiation
factor and blocks protein synthesis [33].
The antiviral activity of RBV against HCV is mediated
through a number of mechanisms which include: (i) inhibition of
cellular IMPDH required for de novo synthesis of guanosine
triphosphate, (ii) RBV triphosphate directly inhibits HCV RNA
polymerase activity, (iii) RBV can be incorporated into viral
genome by HCV RNA polymerase causing mutation in the viral
genome, (iv) RBV enhances IFN-α signaling by inducing the
Figure 4.  Analysis for synergistic effect of IFN-α + IFN-λ, IFN-α + RBV, and IFN-λ + RBV using Calcusyn and MacSynergyII
software.  (A) CalcuSyn software analysis show that IFN-α + RBV combination treatment has a very strong synergy antiviral activity
against HCV IRES mediated inhibition with combination index, CI<1. (B) IFN-λ + RBV combination treatment also has a very strong
synergy antiviral activity with CI<1. (C) IFN-α + IFN-λ treatment are either additive or slightly antagonistic. Three dimensional
inhibition plots of (D) IFN-α + RBV, (E) IFN-λ + RBV and (F) IFN-α + IFN-λ treatment against HCV IRES mediated inhibition of Rluc
at 95% confidence interval synergy plot. Three dimensional synergy plot of (G) IFN-α + RBV, (H) IFN-λ + RBV, and (I) IFN-λ + IFN-
α.
doi: 10.1371/journal.pone.0072791.g004
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Figure 5.  The distribution of HCV IRES-GFP mRNA in the monosome and polysomes fractions in the Huh-7 cells with (+)
and without (-) IFN-α and RBV treatment.  (A) Illustrates the separation of monosome and polysomes along the sucrose gradient
fractions (1 to 14). The values indicate the spectrophotometry of optical density of the polysome fractions at 260 nm wavelengths.
The point arrow shows the 60S, 80S and separation between monosomes and polysomes in the gradient fractions. (B)
Formaldehyde agarose gel electrophoresis and ethidium bromide staining of RNA samples isolated from the corresponding gradient
fractions of untreated Huh-7 cells. The 18S and 28S band appears on the gel throughout the fractions and it become more intense
on the 80S fractions of the gradient as expected. (C) Shows the distribution of HCV IRES-GFP mRNA in the monosome and
polysome fractions by Northern blot analysis using a riboprobe targeted to the 5’ UTR. In the untreated IFN (-) cells the IRES-GFP
mRNA efficiently translated and formed polyribosome complexes (Lane 11-14). But the IFN treatment (+) prevented polysome
formation on IRES-GFP mRNA (Lane 11-14). (D) In the RBV untreated Huh-7 cells, the IRES-GFP mRNA efficiently translated and
formed polyribosome complexes (Lane 11-14). RBV treatment (+) prevented polysome formation on IRES-GFP mRNA (Lane
10-14). (E) Similar experiment was performed where the effect of IFN-α or RBV treatment on the distribution of EGFP mRNA was
examined by Northern blotting using RNA probe specific to GFP. IFN-α treatment did not alter the distribution of EGFP mRNA that
translates by non-IRES dependent mechanism. (F) Comparison of the relative amount of HCV IRES and non-IRES mRNAs in
monosome and polysome fractions in the sucrose density gradient analysis generated from the transfected cells. Density of the
Northern blot was measured using an image analysis computer software (Total Lab, TL120). Values are expressed as percentage
of total mRNA recovered from the gradient versus the mRNA present in each fraction. (G) The formation of polyribosome of EGFP
mRNA was not altered by IFN-α treatment.
doi: 10.1371/journal.pone.0072791.g005
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expression of interferon-stimulated genes (ISG), (v) RBV also
inhibits cellular eIF4E activity required for translation of viral
genome, and (vi) RBV helps to clear the virus by stimulating
the T helper 1 response of host. Among these candidate
mechanisms inhibition of cellular IMPDH by RBV has been
verified by a number of laboratories using HCV and other virus
infection models [34–37]. Molecular studies of RBV action
against HCV are possible due to the availability of in vitro cell
Figure 6.  Western blot analysis of polyribosome fractions of HCV IRES-GFP transfected cells.  (A) Untreated HCV IRES-
GFP transfected cells showing IMPDH, PKR, pPKR is bound to the ribosome throughout the gradient. (B) PKR induced peIF2α
protein is found in the monosome-containing fractions (lanes 1-5) and absent in the higher density polyribosome fractions (lanes
6-10) due to IFN-α treatment. (C) IMPDH, pPKR and peIF2α proteins were found in the monosome fractions (lanes 1-6) but
excluded from the high-density polyribosome fractions (lanes 6-10). The level of actin was detected throughout the gradient.
doi: 10.1371/journal.pone.0072791.g006
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culture systems. A number of new studies support the RBV
antiviral mechanism against HCV replication through inhibition
of cellular IMPDH and reduction of GTP pool [37–40]. Mori et al
[37] reported that the predominant antiviral mechanism of RBV
against HCV is through the inhibition of inosine
monophosphate dehydrogenase (IMPDH) not though the error
catastrophe, the IFN signaling or oxidative stress. This study is
supported by results of other investigators who showed that
decrease in GTP also leads to suppression of HCV RNA
synthesis by NS5B RNA polymerase [38]. The mechanism of
IMPDH inhibition by RBV is supported by the report of Zhou et
al [39] indicating that exogenous guanosine suppressed the
RBV effect where as potent IMPDH inhibitors MPA and VX-497
enhanced RBV antiviral effect. IMPDH modulates intracellular
guanosine nucleotide levels. Therefore it affects a number of
cellular processes involved in translation, cell proliferation and
RNA/DNA synthesis. IMPDH catalyzes the important step in
guanine nucleotide biosynthesis. IMPDH has been shown to be
associated with polyribosome, suggesting that this house-
keeping gene plays an important role in translational regulation
[41]. In our study we found that the distribution of IMPDH is
halted in monosome and disome fraction and absent in
polysome fractions supporting the role IMPDH in HCV IRES
mediated translation.
Ribavirin in combination with IFN-α showed a marked
improvement in the sustained antiviral response in chronic
HCV infection. The synergistic antiviral mechanism of IFNα and
RBV combination therapy is not known. Only a few studies
have been published which explain why RBV and IFN-α
combination treatment is highly effective against HCV
replication [42–46]. Thomas et al [42] showed that RBV
enhanced the IFN-α antiviral activity by inducing the expression
of interferon inducible genes (ISGs) and interferon regulatory
factor (IRF-7) and (IRF-9). Stevenson et al [43] showed that
RBV enhanced IFN-α induced phosphorylation of Stat1, Stat3
and MxA expression and enhanced IFN-α induced cellular Jak-
Stat pathway. Liu et al [44] showed that RBV enhances IFN-α
signaling through activation of separate antiviral signaling by
inducing the expression of cellular p53. This finding is
supported by a report indicating that p53 plays an important
role in host antiviral defense mechanisms and directly inhibits
HCV replication [45]. A previous report by Liu et al [46]
Figure 7.  IFN-α and RBV synergy antiviral mechanism involves the activation of PKR, eIF2α and inhibition of cellular
IMPDH.  (A) IFN-α and RBV each induced phosphorylation of PKR and eIF2α. (B) Flow cytometric analysis showing RBV show a
dose dependent inhibition of HCV IRES-GFP translation. (C) Inhibition of IMPDH and PKR levels by siRNA prevented RBV antiviral
action against HCV IRES-GFP translation determined by flow cytometric analysis. (D) Dose dependent prevention of RBV action
due to increasing concentration of guanosine was determined by flow cytometric analysis. (E) IFN-α inhibits HCV IRES-GFP
translation. (F) Inhibition of PKR by siRNA prevented IFN-α mediated inhibition of HCV IRES-GFP translation.
doi: 10.1371/journal.pone.0072791.g007
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indicates that RBV enhances the IFN-α antiviral activity through
the up-regulation of PKR activity. None of these studies have
shown the synergistic antiviral effect of IFN-α and RBV
combination treatment using HCV cell culture. Our results
indicate IFN-α and RBV combination treatment synergistically
inhibit HCV replication in replicon and infected cell culture
models. We show here for the first time that the synergy
antiviral action of IFN-α and RBV combination therapy is at the
level of inhibition of HCV IRES mediated translation. IFN-α
directly inhibits HCV IRES translation by preventing
polyribosome loading through PKR mediated eIF2α
phosphorylation. Ribavirin inhibits HCV IRES translation by
preventing the polyribosome loading of HCV IRES mRNA.
Ribavirin mediated blockage of polyribosome loading involves
two important mechanisms that involve PKR and IMPDH.
Ribavirin mediated PKR and eIF2α phosphorylation inhibits the
recycling of eIF2α and inhibits HCV IRES translation. Ribavirin
mediated inhibition of IMPDH activity decreases the cellular
GTP pool, which inhibits the HCV-IRES translation by
preventing polyribosome loading. This is supported by the
results showing that pretreatment of guanosine prevented RBV
mediated HCV IRES-GFP translation. Based on these
observations, we propose a model explaining how RBV
mediated depletion of GTP pool and activation of PKR by IFN-α
and RBV combination treatment could be playing an important
role in the synergy antiviral mechanism (Figure 8). The detailed
mechanism how IFN-α and RBV combination treatment leads
to efficient translation arrest of HCV IRES mRNA will be the
topic of future investigation.
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Figure 8.  Diagram summarized the proposed IFN-α and RBV synergy antiviral mechanisms against HCV IRES-GFP
translation.  IFN-α binds to the cell surface receptor, which activates the cellular Jak-Stat pathway leading to the activation of PKR.
The activated PKR phosphorylates the eIF-2α. Phosphorylation of eIF-2α inhibits the recycling of initiation factors and translation
initiation. On the other hand, RBV activates the PKR and eIF2 α phosphorylation and inhibits the translation initiation. Ribavirin
inhibits HCV IRES translation by inhibiting IMPDH and GTP pool.
doi: 10.1371/journal.pone.0072791.g008
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Supporting Information
Figure S1.  HCV genomic and sub-genomic constructs and
cell culture models used to study IFN-α and RBV antiviral
synergy mechanisms.
(A) HCV full-length JFH1-RLuc chimera clone (13) used in the
infectivity assay and sub-genomic HCV RNA used to generate
stable S3-GFP replicon cell line (12). (B) Structure of pHCV
IRES-GFP and pHCV-IRES-Rluc plasmid clone used for this
study. The HCV-IRES-sequences were transcribed from T7
promoter and the 3’ UTR sequences were added at the 3’ end
of GFP or RLuc. pEGFP-N1 and pDsRed-N1 plasmids were
used as controls. (C) Shows the steps used to express HCV
IRES-GFP or HCV IRES-RLuc using a recombinant adenovirus
expressing T7 RNA polymerase.
(TIF)
Figure S2.  MTT assay showing the effect of IFN-α and RBV
combination treatment on viability of Huh-7 and S3-GFP
cells.
(A) Huh-7 cells were treated with increasing concentration of
RBV (10-200 µg/mL) for 48 hours and the viability was
measured. (B) S3-GFP cells were treated with indicated
concentrations of RBV or IFN-α and cell viability was
determined at 48 hours. (C) Cell viability of combination
treatment of IFN-α and RBV at various combinations. S3-GFP
cells were treated with different concentration of RBV with one
concentration of IFN-α for 48 hours and cell viability was
determined by MTT assay.
(TIF)
Figure S3.  Effect of IFN-α and RBV treatment on (A) GFP
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